BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -81.82% | -82.21% | 0.71% | -7.80% | -9.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.82% | -82.21% | 0.71% | -7.80% | -9.84% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -81.82% | -82.21% | 0.71% | -7.80% | -9.84% |
| SG&A Expenses | 34.63% | -34.91% | -47.85% | 27.87% | -10.12% |
| Depreciation & Amortization | 142.11% | 47.42% | 72.04% | 111.36% | -42.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.46% | -21.67% | -34.05% | 18.16% | -29.41% |
| Operating Income | -76.76% | 17.61% | 36.34% | -20.39% | 31.34% |
| Income Before Tax | -14.05% | 12.91% | 33.98% | -1.31% | 20.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.05% | 12.91% | 33.98% | -1.31% | 20.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.05% | 12.91% | 33.98% | -1.31% | 20.00% |
| EBIT | -76.76% | 17.61% | 36.34% | -20.39% | 31.34% |
| EBITDA | -77.91% | 17.75% | 36.63% | -20.54% | 31.76% |
| EPS Basic | -766.67% | 25.00% | 42.00% | 17.65% | 91.43% |
| Normalized Basic EPS | -700.00% | 25.00% | 41.94% | 19.05% | 90.91% |
| EPS Diluted | -766.67% | 25.00% | 42.00% | 17.65% | 91.43% |
| Normalized Diluted EPS | -700.00% | 25.00% | 41.94% | 19.05% | 90.91% |
| Average Basic Shares Outstanding | -88.13% | 15.63% | 15.63% | 23.29% | 938.55% |
| Average Diluted Shares Outstanding | -88.13% | 15.63% | 15.63% | 23.29% | 938.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |